Thymic carcinoma medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Marjan Khan (talk | contribs) No edit summary |
||
| (6 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Thymic carcinoma}} | {{Thymic carcinoma}} | ||
{{CMG}}; {{AE}} {{ | {{CMG}}; {{AE}} {{Marjan}} | ||
==Overview== | ==Overview== | ||
The predominant therapy for thymic carcinoma is surgical resection. Adjunctive cisplatin- | The predominant therapy for thymic carcinoma is surgical resection. Adjunctive cisplatin-based chemotherapy may be required.<ref name=age>National Cancer Institute. General Information About Thymoma and Thymic Carcinoma Treatment. http://www.cancer.gov/types/thymoma/hp/thymoma-treatment-pdq. Accessed on 22nd December, 2015.</ref> | ||
==Medical Therapy== | ==Medical Therapy== | ||
Medical treatment options for thymic carcinoma include the following:<ref name=age>National Cancer Institute. General Information About Thymoma and Thymic Carcinoma Treatment. http://www.cancer.gov/types/thymoma/hp/thymoma-treatment-pdq. Accessed on 22nd December, 2015.</ref> | |||
* | *CAP regimen (cyclophosphamide, doxorubicin, cisplatin): this is the first-line regimen | ||
*Sunitinib<ref name="pmid25592632">{{cite journal| author=Thomas A, Rajan A, Berman A, Tomita Y, Brzezniak C, Lee MJ et al.| title=Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. | journal=Lancet Oncol | year= 2015 | volume= 16 | issue= 2 | pages= 177-86 | pmid=25592632 | doi=10.1016/S1470-2045(14)71181-7 | pmc=4401497 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25592632 }} </ref> | |||
*Gemcitabine | |||
*Docetaxel | |||
*Checkpoint inhibitors | |||
*Radiation | *Radiation | ||
Multimodality approach, such as: | Multimodality approach, such as: | ||
| Line 18: | Line 23: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Hematology]] | |||
[[Category:Immunology]] | |||
[[Category:Surgery]] | |||
Latest revision as of 18:38, 10 September 2019
|
Thymic Carcinoma Microchapters |
|
Diagnosis |
|---|
|
Case Studies |
|
Thymic carcinoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Thymic carcinoma medical therapy |
|
Risk calculators and risk factors for Thymic carcinoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Marjan Khan M.B.B.S.[2]
Overview
The predominant therapy for thymic carcinoma is surgical resection. Adjunctive cisplatin-based chemotherapy may be required.[1]
Medical Therapy
Medical treatment options for thymic carcinoma include the following:[1]
- CAP regimen (cyclophosphamide, doxorubicin, cisplatin): this is the first-line regimen
- Sunitinib[2]
- Gemcitabine
- Docetaxel
- Checkpoint inhibitors
- Radiation
Multimodality approach, such as:
- Surgical resection
- Radiation therapy
- Cisplatin-based chemotherapy
References
- ↑ 1.0 1.1 National Cancer Institute. General Information About Thymoma and Thymic Carcinoma Treatment. http://www.cancer.gov/types/thymoma/hp/thymoma-treatment-pdq. Accessed on 22nd December, 2015.
- ↑ Thomas A, Rajan A, Berman A, Tomita Y, Brzezniak C, Lee MJ; et al. (2015). "Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial". Lancet Oncol. 16 (2): 177–86. doi:10.1016/S1470-2045(14)71181-7. PMC 4401497. PMID 25592632.